Simvastatin: the pathway in the body

Simvastatin is part of the pathway “Simvastatin”. This page shows the whole pathway; the station of Simvastatin is highlighted.

Where this laboratory value sits: Simvastatin — lactone, as a tablet. Simvastatin is swallowed as a closed ring, a lactone. In this form it is not yet the shape of the molecule that acts at the enzyme. Only the opened form acts at the enzyme. Source 1, 7

In brief

Simvastatin is a statin. In the body it turns into the open acid form, which settles into the binding pocket of HMG-CoA reductase, the enzyme that converts HMG-CoA into mevalonate. The pocket is occupied only while the substance is present. Both cholesterol and Q10 are slowed.

The pathway step by step

Each station states what the compound does there. Three signs: ↑ supplies — builds up or makes available · ↓ depletes — inhibits, consumes or withholds · ↕ both, depending on amount. Behind it stands what the statement rests on: established physiology, observed in studies, or contested. The signs do not grade; they name the direction.

1. Simvastatin → Simvastatin acid · water In the body the ring is opened; the β-hydroxy acid arises, called simvastatin acid. This open form resembles the molecular part HMG. It displaces HMG-CoA from the binding pocket. Source 1, 7↓ depletes The acid form resembles HMG-CoA and displaces it from the binding pocket of the reductase. It binds there far more tightly than the actual substrate. established physiology Source 2, 7
   ⚖ When the balance tips

   too much — If a lot of acid form is present, more enzyme pockets are occupied, and the path to mevalonate runs more slowly; the cell then makes more reductase.

   too little — If little acid form is present, more pockets stay free for HMG-CoA, and the reductase works close to its usual pace.

   established physiology · Source 2, 5

2. Simvastatin acid → In the liver cell The liver picks up most of it already on the first passage from the portal blood. Only a small part reaches the rest of the circulation. The substance thus acts mainly in the liver. Source 7↑ supplies Because the liver picks up the substance on the first passage, it acts mainly where most of the body's own cholesterol is made. The rest of the circulation receives only a little. established physiology Source 7
   ⚖ When the balance tips

   too much — If a lot of the substance gets past the liver filter, for example when CYP3A4 is inhibited, the amount in the rest of the circulation rises, and tissues outside the liver receive more of it.

   too little — If the liver picks up the substance almost completely and breaks it down quickly, very little remains in the rest of the circulation, and other tissues are hardly reached.

   established physiology · Source 7

3. In the liver cell → Excretion CYP3A4 In the liver cell the enzyme CYP3A4 converts the substance further. The breakdown products leave the body mostly with bile and stool, a smaller part with the urine. This ends its action. Source 7↓ depletes CYP3A4 converts the substance into breakdown products and so ends its action. Most of it leaves the body via the bile. established physiology Source 7
   ⚖ When the balance tips

   too much — If CYP3A4 works quickly, for example because other substances cause more of the enzyme to be made, the amount of simvastatin in the blood falls, and fewer enzyme pockets are occupied.

   too little — If CYP3A4 works slowly, for example because other medicines inhibit it, more of the substance and the acid form remain in the blood and stay longer in the body.

   established physiology · Source 7

4. Acetyl-CoA → HMG-CoA HMG-CoA synthase HMG-CoA is the substance at which the pathway is governed. The next enzyme sets how much mevalonate arises. It competes with simvastatin for the binding pocket. Source 3↑ supplies HMG-CoA is the substrate of the reductase and stands at the entrance to the governed step. It competes with the acid form of simvastatin for the same binding pocket. established physiology Source 3, 2
   ⚖ When the balance tips

   too much — If HMG-CoA builds up because the reductase is inhibited, more of it competes with the acid form for the pocket.

   too little — If little HMG-CoA is present, the acid form gets into the pocket more easily, and the reductase converts little.

   established physiology · Source 2

5. HMG-CoA → Mevalonate HMG-CoA reductase · NADPH HMG-CoA reductase converts HMG-CoA into mevalonate and uses up two NADPH. This step sets the pace of the whole pathway. When it is slowed, all branches receive less. Source 3, 2↑ supplies Mevalonate is the starting material of all isoprenes. From it arise cholesterol, coenzyme Q10 and anchor groups with which cells attach proteins to membranes. established physiology Source 3, 4
   ⚖ When the balance tips

   too much — If a lot of mevalonate forms and with it a lot of sterol, the cells break down the reductase more quickly and slow its renewal.

   too little — If little mevalonate forms, all following branches receive less starting material: cholesterol, coenzyme Q10 and the isoprene anchors.

   established physiology · Source 3, 4

6. Mevalonate → Farnesyl-PP several enzymes · ATP From mevalonate come activated isoprene units, which are joined into farnesyl pyrophosphate. Here the pathway splits into several branches. What is scarce here is scarce for all branches. Source 4↑ supplies Farnesyl-PP distributes the material to the branches: squalene and cholesterol, decaprenyl-PP for coenzyme Q10, and anchors for proteins. What is scarce here is scarce for all branches at once. established physiology Source 4, 3
   ⚖ When the balance tips

   too much — If a lot of farnesyl-PP is available, a large share flows via squalene into the making of cholesterol.

   too little — If little farnesyl-PP is available, the branches compete for the pool; in studies the branches to the protein anchors stay supplied more readily than the path to squalene.

   observed in studies · Source 3, 4

7. Farnesyl-PP → Cholesterol squalene synthase etc. · NADPH, oxygen One branch runs via squalene to cholesterol, a building block of every cell membrane and the starting material for bile acids and steroid hormones. It also signals to the cell how much is present. Source 3↑ supplies Cholesterol builds membranes and is the starting material for bile acids and steroid hormones. At the same time it signals to the cell via SREBP-2 how much of it is present. established physiology Source 3, 5
   ⚖ When the balance tips

   too much — If a lot of cholesterol is present in the liver cell, SREBP-2 is held back in the endoplasmic reticulum, and less reductase and fewer LDL receptors are made.

   too little — If little cholesterol is present, SREBP-2 moves into the cell nucleus and switches on the genes for reductase and LDL receptors.

   established physiology · Source 5

8. Cholesterol → LDL receptors SREBP-2 When cholesterol in the liver cell falls, the regulator SREBP-2 releases more LDL receptors. They fetch LDL particles out of the blood into the cell. More receptors lower the LDL in the blood. Source 5, 7↑ supplies The LDL receptors bring LDL particles, together with cholesterol and the coenzyme Q10 travelling with them, into the liver cell. More receptors thus lower the LDL in the blood. established physiology Source 5, 6, 7
   ⚖ When the balance tips

   too much — If many LDL receptors are on the surface, more LDL is drawn from the blood, and the LDL level in the blood falls.

   too little — If there are few receptors, LDL stays in the blood longer, and the liver cell obtains more cholesterol from its own synthesis.

   established physiology · Source 5, 7

9. Farnesyl-PP → Decaprenyl-PP PDSS1, PDSS2 Another branch lengthens the chain to ten isoprene units. It becomes the tail of coenzyme Q10. It depends on the same farnesyl-PP as cholesterol. Source 4↑ supplies Decaprenyl-PP supplies the long tail that anchors coenzyme Q10 in the inner mitochondrial membrane. Its formation depends on the same farnesyl-PP as the formation of cholesterol. established physiology Source 4
   ⚖ When the balance tips

   too much — If a lot of decaprenyl-PP is available, COQ2 can attach more of it to the ring, provided enough 4-hydroxybenzoate is present.

   too little — If little decaprenyl-PP is available because less mevalonate forms upstream, less coenzyme Q10 is made.

   observed in studies · Source 4, 6

10. Decaprenyl-PP → Coenzyme Q10 COQ2 and COQ enzymes · 4-hydroxybenzoate The enzyme COQ2 attaches the chain to a ring made of 4-hydroxybenzoate. Further COQ enzymes rebuild the ring; ubiquinone is complete with that. It transfers electrons in the mitochondria. Source 4↑ supplies In the mitochondria, coenzyme Q10 transfers electrons from complexes I and II to complex III and so contributes to ATP formation. In its reduced form it intercepts radicals in membranes. established physiology Source 4
    ⚖ When the balance tips

    too much — If a lot of coenzyme Q10 is present, the respiratory chain is well stocked with electron carriers, and more reduced Q10 is available in membranes to intercept radicals.

    too little — If little coenzyme Q10 is present, electrons are passed on more slowly; lower Q10 levels in the blood have been described with statins, partly because fewer LDL particles carry it.

    observed in studies · Source 4, 6

Further stations

• Simvastatin — lactone, as a tablet Simvastatin is swallowed as a closed ring, a lactone. In this form it is not yet the shape of the molecule that acts at the enzyme. Only the opened form acts at the enzyme. Source 1, 7↑ supplies The lactone is a precursor: it is fat-soluble and passes easily through membranes, but itself hardly acts at the enzyme. Only the opened form settles into the binding pocket. established physiology Source 1, 7
  ⚖ When the balance tips

  too much — If a lot of lactone is present, more of it is opened into the acid form, and the liver cells receive more active substance.

  too little — If little lactone is present, little acid form arises, and more HMG-CoA reductase stays free.

  established physiology · Source 1, 7

• At the binding site — of HMG-CoA reductase The acid form settles into the pocket of the enzyme where HMG-CoA otherwise sits. The enzyme itself sits in the membrane of the endoplasmic reticulum. While it sits there, HMG-CoA cannot bind. Source 2, 7↓ depletes When the acid form occupies the pocket, HMG-CoA cannot bind; the enzyme converts nothing while the substance sits there. The inhibition is reversible and depends on how much of the substance is present. established physiology Source 2, 1
  ⚖ When the balance tips

  too much — If many pockets are occupied, mevalonate formation falls sharply; the cell responds via SREBP-2 with more reductase and more LDL receptors.

  too little — If few pockets are occupied, the reductase runs largely freely, and cholesterol and coenzyme Q10 arise to the usual extent.

  established physiology · Source 2, 5

• Acetyl-CoA — building block from breakdown The mevalonate pathway starts with acetyl-CoA from the breakdown of sugar and fatty acids. Three of these building blocks are joined into HMG-CoA. Every carbon atom of the pathway comes from acetyl-CoA. Source 3, 4↑ supplies Acetyl-CoA supplies every carbon atom of the mevalonate pathway. From it, cholesterol and the isoprene tail of coenzyme Q10 eventually arise. established physiology Source 3, 4
  ⚖ When the balance tips

  too much — If a lot of acetyl-CoA is available, more HMG-CoA forms; how much of it goes on is decided only by the reductase.

  too little — If little acetyl-CoA is available, little HMG-CoA forms, and the whole pathway receives less starting material.

  established physiology · Source 3

What this active substance affects

• Coenzyme Q10 — Its isoprene tail arises from farnesyl-PP, which lies in the same pathway below HMG-CoA reductase Source 4, 6
• Cholesterol — Arises from the same mevalonate; the pathway splits only further down, at farnesyl-PP; it gives rise to bile acids Source 3
• LDL cholesterol — LDL particles carry cholesterol and coenzyme Q10 in the blood; the liver cell fetches them in via LDL receptors Source 5, 6

What takes part in these steps

• NADPH — Electron donor of HMG-CoA reductase; the enzyme uses up two NADPH per mevalonate; scarce NADPH slows the step Source 3
• Tyrosine — Supplies the ring 4-hydroxybenzoate, to which the isoprene chain of coenzyme Q10 is attached; no ring, no coenzyme Q10 Source 4
• SAM (from methionine) — Methyl group donor of the COQ enzymes that rebuild the ring of coenzyme Q10; needed for the finished ring Source 4

What the prescribing information states

One trial in northern Europe with 2,221 adults who received simvastatin and 2,223 who received a placebo, over a median of 5.4 years. Listed are the reactions that occurred in at least 2 of 100 participants and were more common than on placebo. The figures apply to this trial.

How to read the table: this prescribing information lists only reactions that occurred more often on simvastatin than on placebo — reactions of equal or lower frequency are therefore missing. What matters is the distance within the row, and in most rows it is small: for bronchitis and abdominal pain it is less than half a point.

Across all trials together the prescribing information counts 2,423 adults with a median follow-up of about 18 months; there 1.4 of 100 participants stopped because of a reaction. Reactions reported after approval are not listed here — the prescribing information states that neither a frequency nor a causal relationship can be derived from them.

Sources

1. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005 · PubMed 15660968
2. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001 · PubMed 11349148
3. Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J Biol Chem 2013 · PubMed 23696639
4. Guerra RM, Pagliarini DJ. Coenzyme Q biochemistry and biosynthesis. Trends Biochem Sci 2023 · PubMed 36702698
5. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002 · PubMed 11994399
6. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev 2005 · PubMed 15705257
7. US prescribing information (United States): Simvastatin Tablets, DailyMed, version of 25 Aug 2026, sections 12.1 Mechanism of Action, 12.2 Pharmacodynamics and 12.3 Pharmacokinetics · Prescribing information
8. US prescribing information (United States): Simvastatin Tablets, DailyMed, version of 25 Aug 2026, sections 6.1 Clinical Trials Experience and 6.2 Postmarketing Experience · Prescribing information

Whole pathway: Simvastatin

As of 2026-09-25. Draft, written by Claude to schema v2; sources checked in PubMed; expert approval pending
Legal notice Privacy policy All biomarkers